Linked Life Data

2448657

Source:http://linkedlifedata.com/resource/pubmed/id/2448657

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2448657rdf:typepubmed:Citationlld:pubmed
pubmed-article:2448657lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:2448657lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:2448657lifeskim:mentionsumls-concept:C1516238lld:lifeskim
pubmed-article:2448657lifeskim:mentionsumls-concept:C0034656lld:lifeskim
pubmed-article:2448657lifeskim:mentionsumls-concept:C0684224lld:lifeskim
pubmed-article:2448657lifeskim:mentionsumls-concept:C0079744lld:lifeskim
pubmed-article:2448657lifeskim:mentionsumls-concept:C0005740lld:lifeskim
pubmed-article:2448657lifeskim:mentionsumls-concept:C0010583lld:lifeskim
pubmed-article:2448657lifeskim:mentionsumls-concept:C0013089lld:lifeskim
pubmed-article:2448657lifeskim:mentionsumls-concept:C0025677lld:lifeskim
pubmed-article:2448657lifeskim:mentionsumls-concept:C0032952lld:lifeskim
pubmed-article:2448657lifeskim:mentionsumls-concept:C0042679lld:lifeskim
pubmed-article:2448657lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:2448657lifeskim:mentionsumls-concept:C0439611lld:lifeskim
pubmed-article:2448657lifeskim:mentionsumls-concept:C0085752lld:lifeskim
pubmed-article:2448657pubmed:issue5lld:pubmed
pubmed-article:2448657pubmed:dateCreated1988-3-4lld:pubmed
pubmed-article:2448657pubmed:abstractTextBetween 1979 and 1985, 166 patients with diffuse large cell (histiocytic) lymphoma were randomized to receive therapy with 3 courses of cyclophosphamide, doxorubicin (Adriamycin), vincristine, and prednisone (CAVP), with or without low-dose bleomycin, by continuous iv infusion. Responders were further randomized to 3 weeks of therapy with either high-dose methotrexate (3 g/m2 iv weekly with leukovorin rescue) or low-dose methotrexate (30 mg/m2 orally weekly without rescue). Therapy was concluded with 3 additional courses of CAVP. No significant differences among the 4 treatment programs were observed in complete response rates (ranging from 46% to 51%) or in failure-free survival. Of the 38 relapses that have occurred in patients treated with low-dose methotrexate, 5 included relapse in the central nervous system in conjunction with systemic relapse. However, none of 31 relapses observed in patients receiving high-dose methotrexate have occurred with involvement of the central nervous system. Patients entering this study with "B" symptoms had significantly poorer treatment results than those patients entering study without "B" symptoms.lld:pubmed
pubmed-article:2448657pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2448657pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2448657pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2448657pubmed:languageenglld:pubmed
pubmed-article:2448657pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2448657pubmed:citationSubsetIMlld:pubmed
pubmed-article:2448657pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2448657pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2448657pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2448657pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2448657pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2448657pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2448657pubmed:statusMEDLINElld:pubmed
pubmed-article:2448657pubmed:issn0893-2751lld:pubmed
pubmed-article:2448657pubmed:authorpubmed-author:NortonLLlld:pubmed
pubmed-article:2448657pubmed:authorpubmed-author:GottliebA JAJlld:pubmed
pubmed-article:2448657pubmed:authorpubmed-author:AndersonJ RJRlld:pubmed
pubmed-article:2448657pubmed:authorpubmed-author:BloomfieldC...lld:pubmed
pubmed-article:2448657pubmed:authorpubmed-author:BarcosMMlld:pubmed
pubmed-article:2448657pubmed:authorpubmed-author:HollandJ FJFlld:pubmed
pubmed-article:2448657pubmed:authorpubmed-author:GinsbergS JSJlld:pubmed
pubmed-article:2448657pubmed:issnTypePrintlld:pubmed
pubmed-article:2448657pubmed:ownerNLMlld:pubmed
pubmed-article:2448657pubmed:authorsCompleteYlld:pubmed
pubmed-article:2448657pubmed:pagination77-80lld:pubmed
pubmed-article:2448657pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:2448657pubmed:meshHeadingpubmed-meshheading:2448657-...lld:pubmed
pubmed-article:2448657pubmed:meshHeadingpubmed-meshheading:2448657-...lld:pubmed
pubmed-article:2448657pubmed:meshHeadingpubmed-meshheading:2448657-...lld:pubmed
pubmed-article:2448657pubmed:meshHeadingpubmed-meshheading:2448657-...lld:pubmed
pubmed-article:2448657pubmed:meshHeadingpubmed-meshheading:2448657-...lld:pubmed
pubmed-article:2448657pubmed:meshHeadingpubmed-meshheading:2448657-...lld:pubmed
pubmed-article:2448657pubmed:meshHeadingpubmed-meshheading:2448657-...lld:pubmed
pubmed-article:2448657pubmed:meshHeadingpubmed-meshheading:2448657-...lld:pubmed
pubmed-article:2448657pubmed:meshHeadingpubmed-meshheading:2448657-...lld:pubmed
pubmed-article:2448657pubmed:year1987lld:pubmed
pubmed-article:2448657pubmed:articleTitleA randomized trial of high-dose methotrexate versus standard-dose methotrexate following cyclophosphamide, doxorubicin (adriamycin), vincristine, and prednisone with or without bleomycin in the therapy of diffuse large cell lymphoma: preliminary report of Cancer and Leukemia Group B Study 7851.lld:pubmed
pubmed-article:2448657pubmed:affiliationState University of New York Health Science Center, Syracuse.lld:pubmed
pubmed-article:2448657pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2448657pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:2448657pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:2448657pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:2448657pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed